GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianda Pharmaceuticals Ltd (HKSE:00455) » Definitions » Price-to-Owner-Earnings

Tianda Pharmaceuticals (HKSE:00455) Price-to-Owner-Earnings : (As of Jun. 11, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Tianda Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-06-11), Tianda Pharmaceuticals's share price is HK$0.237. Tianda Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Tianda Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Tianda Pharmaceuticals was 83.33. The lowest was 5.17. And the median was 27.14.


HKSE:00455's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.375
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-11), Tianda Pharmaceuticals's share price is HK$0.237. Tianda Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.01. Therefore, Tianda Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-06-11), Tianda Pharmaceuticals's share price is HK$0.237. Tianda Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was HK$-0.01. Therefore, Tianda Pharmaceuticals's PE Ratio without NRI for today is At Loss.

During the past 13 years, Tianda Pharmaceuticals's highest PE Ratio without NRI was 200.00. The lowest was 0.00. And the median was 87.50.


Tianda Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Tianda Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianda Pharmaceuticals Price-to-Owner-Earnings Chart

Tianda Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.00 - - - -

Tianda Pharmaceuticals Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tianda Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Tianda Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianda Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianda Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Tianda Pharmaceuticals's Price-to-Owner-Earnings falls into.



Tianda Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Tianda Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.237/-0.05
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianda Pharmaceuticals  (HKSE:00455) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Tianda Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Tianda Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianda Pharmaceuticals (HKSE:00455) Business Description

Traded in Other Exchanges
N/A
Address
CITIC Tower, No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, Central, Hong Kong, HKG
Tianda Pharmaceuticals Ltd is engaged in R&D, manufactures and sales of pharmaceutical, biotechnology and healthcare products. The group also engages in R&D of Chinese medicine and manufacture and sales of Chinese medicine products, and the provision of Chinese medical services. Its operating segments include Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives majority of the revenue from Pharmaceuticals and medical technologies business.
Executives
Tianda Group Limited 2101 Beneficial owner
Fang Wen Quan 2201 Interest of corporation controlled by you

Tianda Pharmaceuticals (HKSE:00455) Headlines

No Headlines